Search clinical trials for: Bromocriptine Mesylate

Total 1683 results

Vitreous -Retina- Macula Consultants of New York
Genentech, Inc.

Withdrawn

Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Choroidal Neovascularization

United States
Chromaderm, Inc.

Completed

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

Diabetic Neuropathies | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Insulin-Dependent

Canada, United States, Croatia, Finland, India, Lithuania, Netherlands, United Kingdom
NYU Langone Health
Novartis

Terminated

Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin

Ovarian Cancer

United States
Kyoto University
Osaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaborators

Completed

Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease (REBRAnD)

Familial Alzheimer Disease (FAD) | PSEN1 Mutation

Japan
Lee's Pharmaceutical Limited

Unknown

Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol

Otitis Media

China
M.D. Anderson Cancer Center
Gemin X

Terminated

Obatoclax for Systemic Mastocytosis

Leukemia | Systemic Mastocytosis

United States
Beijing Chao Yang Hospital

Not yet recruiting

The Effect of Wavelet Index in Monitoring the Sedation Depth of Remimazolam Besylate

Anesthesia Awareness | Remimazolam | Sedative, Hypnotic, or Anxiolytic Withdrawal
Duke University
National Cancer Institute (NCI)

Completed

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Brain and Central Nervous System Tumors

United States
Meng Li

Unknown

Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia (SESPI)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

Kidney Cancer

United States
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Terminated

Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma

Solid Tumor | Thyroid Cancer

United States
Gruppo Italiano MEsotelioma

Unknown

A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma

Mesothelioma

Italy
Bausch & Lomb Incorporated

Completed

Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Cleave Therapeutics, Inc.

Completed

Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Acute Myeloid Leukemia, in Relapse

United States, Australia
Dongguan HEC Biopharmaceutical R&D Co., Ltd.

Recruiting

Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

China
Boston Children's Hospital

Completed

Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis (PVS)

Pulmonary Veno Occlusive Disease

United States
IWK Health Centre

Unknown

Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study (PCOS-Pilot)

Insulin Resistance | PCOS

Canada
Istituto Clinico Humanitas

Completed

Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma

Mesothelioma, Malignant

Italy
National Cancer Institute (NCI)

Completed

Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Annick Desjardins
AstraZeneca; Novartis Pharmaceuticals

Completed

Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma

Glioblastoma | Gliosarcoma

United States
Pfizer

Terminated

Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumor

United States, Korea, Republic of, Spain, United Kingdom, Italy, Germany, Hong Kong
Tongji Hospital

Recruiting

ED90 of Remimazolam Anesthesia Induction in Drug-induced Sleep Endoscopy in Adults

Effect of Drug

China
Zhihong LU

Not yet recruiting

Dose of Remi in Children (DRINK)

Anesthesia
Seoul National University Hospital

Recruiting

Dose Finding Study for Remimazolam in Children

Drug Effect

Korea, Republic of
Eisai Korea Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea

Parkinson Disease

Korea, Republic of
Seoul National University Bundang Hospital

Completed

Remimazolam vs Desflurane for General Anesthesia for Ablation of Arrhythmia

Arrhythmia | Desflurane | General Anesthesia | Remimazolam | Cryoablation

Korea, Republic of
Boehringer Ingelheim

Completed

Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease

Parkinson Disease

China
Seoul National University Hospital

Terminated

Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children

Chronic Graft-versus-host Disease

Korea, Republic of
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Commissie Voor Klinisch Toegepast Onderzoek

Unknown

Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia

Leukemia

Netherlands, Belgium
National Cancer Institute (NCI)

Terminated

Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery

Gastrointestinal Stromal Tumor

United States
University of Washington
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
Tongji Hospital

Recruiting

ED90 of Remimazolam Anesthesia Induction in Painless Bidirectional Endoscopy in Children (ED90)

Bidirectional Endoscopy

China
North Texas Institute for Clinical Trials

Completed

The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing

Histamine Responsive Allergy Patients

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Novartis

Terminated

Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer

Lung Cancer

United States
Northwestern University
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer

Pancreatic Cancer

United States
Second Affiliated Hospital of Wenzhou Medical University

Not yet recruiting

Effect of Esketamine on 95% Induction Dose of Remimazolam (EEIDR)

Sedation | Pediatric | Gastroscopy | ED95

China
Sunshine Lake Pharma Co., Ltd.

Not yet recruiting

A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML

Acute Myeloid Leukemia, Adult

China
Arog Pharmaceuticals, Inc.

Completed

A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations

Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Novartis Pharmaceuticals; Rutgers Cancer Institute...

Terminated

Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer

Breast Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia

Accelerated Phase Chronic Myelogenous Leukemia | Childhood Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous Leukemia

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Eisai Inc.
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (ENHANCE-1)

Breast Neoplasm

United States
Eisai Limited

Completed

A Confirmation Study of Eribulin in Combination With Capecitabine

Metastatic Breast Cancer

United Kingdom, Bulgaria, Russian Federation
Eisai Inc.

Completed

E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Metastatic Breast Cancer

Poland, Ukraine, United States, Taiwan, Spain, Argentina, Bulgaria, Romania, South Africa, Australia, Canada, Singapore, Russian Federation, Brazil, Germany, Hungary, Italy, Israel, Greece, Mexico, Belgium, Czechia, France
Laboratorios Sophia S.A de C.V.

Completed

Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+ (PRO-172)

Tolerability | Safety | Ocular Surface | Ocular Comfort

Mexico
Eisai Inc.
Halozyme Therapeutics

Terminated

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Metastatic Breast Cancer

United States
Montreal Heart Institute
Canadian Cardiovascular Society

Withdrawn

Bromocriptine in the Treatment of Peripartum Cardiomyopathy (BRO-HF)

Peripartum Cardiomyopathy

Canada

Search clinical trials for: Bromocriptine Mesylate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations